Ocrevus (ocrelizumab)

Information on this site is not intended as medical advice and should not be used as a substitute for consulting with a qualified doctor.

Ocrelizumab is a recombinant humanized monoclonal antibody that selectively targets CD20-expressing B-cells 1. By reducing the number of these B cells, Ocrevus helps slow disease progression, reduce relapses, and limit the development of brain lesions .

In Bangladesh, Ocrevus is approved for the following indication(s)1:

  • OCREVUS is indicated for the treatment of patients with relapsing forms of multiple sclerosis (RMS) to suppress relapses and disease progression (clinical and subclinical disease activity).

  • OCREVUS is indicated for the treatment of patients with primary progressive multiple sclerosis (PPMS) to delay disease progression and reduce deterioration in walking speed.

For more disease and treatment related queries, it is recommended that you discuss with your physicians in details.

In Bangladesh, Ocrevus is available as

  • Vial 300 mg / 10 ml

is the authorized importer and distributor for Roche pharmaceutical medicines in Bangladesh. To meet strict quality and compliance, Radiant maintains temperature controlled supply chain.

To ensure patient safety and quality, it is strongly recommended to verify that, each medicine comes with the Roche Hologram Sticker, DGDA approved DAR (Drug Administration Registration) Number imprinted on it. Neither Radiant nor Roche Bangladesh takes liability of any other sources of products.

References

  1. Ocrevus Product Information _ BD RO4964913_April 2022

Downloads

Ocrevus Product Information _ BD RO4964913_April 2022

Discover more

Contact